Literature DB >> 26899413

Clinical characteristics and antimicrobial patterns in complicated intra-abdominal infections: a 6-year epidemiological study in southern China.

Wenwei Ouyang1, Huiling Xue2, Yunqin Chen3, Weiguo Gao3, Xiaoyan Li1, Jia Wei4, Zehuai Wen5.   

Abstract

Complicated intra-abdominal infection (cIAIs) are a common and important cause of morbidity worldwide. In this study, the clinical features, microbiological profiles, antimicrobial patterns and treatments of 3233 cIAI patients (mean age, 47.6 years; 54.7% male) with 3531 hospitalisations from 2008-2013 were retrospectively investigated. The most commonly isolated bacteria were Escherichia coli (47.6%), Klebsiella pneumoniae (16.9%), Enterococcus faecalis (10.4%) and Pseudomonas aeruginosa (8.8%). Ciprofloxacin, aminoglycoside (gentamicin), piperacillin/tazobactam and carbapenems exhibited activity against 53%, 76%, 88% and 100% of extended-spectrum β-lactamase (ESBL)-positive Enterobacteriaceae isolates, respectively. Pseudomonas aeruginosa isolates exhibited 100%, 95%, 88%, 71% and 76% susceptibility to aminoglycoside (gentamicin), ciprofloxacin, meropenem, imipenem and ceftazidime, respectively, and Enterococcus remained 100% susceptible to vancomycin and linezolid. β-Lactam antibacterials other than penicillin (specifically third-generation cephalosporins) and imidazole derivatives (ornidazole and metronidazole) were the most common first-line treatments. Patients subjected to regimen change after initial antibiotic treatment had predisposing conditions (e.g. older age, more severe co-morbidities) and a higher incidence of P. aeruginosa infection; in addition, these patients encountered a higher average cost of care and worse clinical outcomes compared with those without medication modification. Taken together, these findings indicate the importance of appropriate initial empirical therapy and suggest the use of combination therapy comprising cephalosporins and metronidazole.
Copyright © 2016 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Antibiotic resistance; Complicated intra-abdominal infection; Cost of care; ESBL-positive Enterobacteriaceae; Empirical antibiotic therapy; Pseudomonas aeruginosa

Mesh:

Substances:

Year:  2016        PMID: 26899413     DOI: 10.1016/j.ijantimicag.2015.12.019

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  7 in total

Review 1.  Antimicrobial Lessons From a Large Observational Cohort on Intra-abdominal Infections in Intensive Care Units.

Authors:  Dirk Vogelaers; Stijn Blot; Andries Van den Berge; Philippe Montravers
Journal:  Drugs       Date:  2021-05-26       Impact factor: 9.546

2.  Clinical and Microbiological Characteristics of Patients with Complicated Intra-abdominal Infections in Intensive Care Unit.

Authors:  Yang-Mei Xiong; Xin Rao
Journal:  Curr Med Sci       Date:  2020-03-13

3.  Effect of multiple drug resistance on total medical costs among patients with intra-abdominal infections in China.

Authors:  Xuemei Zhen; Yuanyuan Li; Yixi Chen; Peng Dong; Stephanie Liu; Hengjin Dong
Journal:  PLoS One       Date:  2018-03-28       Impact factor: 3.240

4.  A multicenter, double-blind, randomized, comparison study of the efficacy and safety of tigecycline to imipenem/cilastatin to treat complicated intra-abdominal infections in hospitalized subjects in China.

Authors:  Yijian Chen; Demei Zhu; Yingyuan Zhang; Yongjie Zhao; Gang Chen; Ping Li; Lihong Xu; Ping Yan; M Anne Hickman; Xiajun Xu; Margaret Tawadrous; Michele Wible
Journal:  Ther Clin Risk Manag       Date:  2018-11-30       Impact factor: 2.423

5.  Susceptibility breakpoint for Danofloxacin against swine Escherichia coli.

Authors:  Yuqi Yang; Yixin Zhang; Jiarui Li; Ping Cheng; Tianshi Xiao; Ishfaq Muhammad; Hongxiao Yu; Ruimeng Liu; Xiuying Zhang
Journal:  BMC Vet Res       Date:  2019-02-04       Impact factor: 2.741

6.  Optimising the treatment for uncomplicated acute appendicitis (OPTIMA trial): a protocol for a multicentre, randomised, double-blinded placebo-controlled study.

Authors:  Jie Wu; Haiyang Jiang; Shikuan Li; Xiuwen Wu; Peige Wang; Robert Sawyer; Jianan Ren
Journal:  BMJ Open       Date:  2022-05-02       Impact factor: 3.006

7.  Pharmacokinetics of Linezolid Dose Adjustment for Creatinine Clearance in Critically Ill Patients: A Multicenter, Prospective, Open-Label, Observational Study.

Authors:  Xipei Wang; Yifan Wang; Fen Yao; Shenglong Chen; Yating Hou; Zhijie Zheng; Jinbiao Luo; Binghui Qiu; Zhanfu Li; Yirong Wang; Zheng Wu; Jinhua Lan; Chunbo Chen
Journal:  Drug Des Devel Ther       Date:  2021-05-19       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.